Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679051 | 0.95 | CA2 (0.40) | CA2CA1PLA2G2CALDH1A1DNM1 | |
| SCHEMBL1678453 | 0.95 | PLA2G2C (0.43) | CA2CA1PLA2G2CDNM1FDPS | |
| SCHEMBL7596054 | 0.92 | LMNA (0.44) | CA1PLA2G2CFDPSLMNA | |
| SCHEMBL6442867 | 0.89 | LMNA (0.48) | PLA2G2CDNM1TSHRFDPSLMNA | |
| SCHEMBL1679088 | 0.89 | — | — | |
| SCHEMBL26488738 | 0.89 | LMNA (0.48) | PLA2G2CDNM1TSHRFDPSLMNA | |
| SCHEMBL6064879 | 0.89 | LMNA (0.48) | PLA2G2CDNM1TSHRFDPSLMNA | |
| SCHEMBL1275849 | 0.89 | LMNA (0.48) | PLA2G2CDNM1TSHRFDPSLMNA | |
| SCHEMBL6266680 | 0.89 | LMNA (0.48) | PLA2G2CDNM1TSHRFDPSLMNA | |
| SCHEMBL11413337 | 0.89 | LMNA (0.48) | PLA2G2CDNM1TSHRFDPSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995029892-A1 | HYDROXAMIC ACID AND AMINO ACID DERIVATIVES AND THEIR USE AS ANTI-ARTHRITIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-11-09 | — | — | WO | claimed |
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1028716-A1 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1995029892-A1 | HYDROXAMIC ACID AND AMINO ACID DERIVATIVES AND THEIR USE AS ANTI-ARTHRITIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | CA2 436/4885CA1 1927/4885PLA2G2C 1853/4885 |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | CA2 4718/4885CA1 2562/4885PLA2G2C 1874/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | CA2 436/4885CA1 1927/4885PLA2G2C 1853/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | CA2 436/4885CA1 1927/4885PLA2G2C 1853/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | CA2 4239/4885CA1 4595/4885PLA2G2C 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.